BTNL2 and neoplasm: Therefore, it has been speculated that therapeutic targeting of MDSCs might offer significant additive or synergistic benefits when combined with ICB therapy, which is supported by our finding that dual-inhibition of PD-1 and BTNL2 bolsters anti-tumour immune responses (Fig. 1f–h).